Jazz Pharmaceuticals Plc (JAZZ)
245.51
+1.80
(+0.74%)
USD |
NASDAQ |
Sep 02, 16:00
245.51
0.00 (0.00%)
After-Hours: 20:00
Jazz Pharmaceuticals Cash from Investing (Quarterly) : 354.90M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 354.90M |
| March 31, 2026 | 123.10M |
| December 31, 2025 | -372.16M |
| September 30, 2025 | -327.80M |
| June 30, 2025 | -641.02M |
| March 31, 2025 | -168.93M |
| December 31, 2024 | -193.29M |
| September 30, 2024 | 214.09M |
| June 30, 2024 | -257.09M |
| March 31, 2024 | -271.90M |
| December 31, 2023 | 101.80M |
| September 30, 2023 | -174.30M |
| June 30, 2023 | -85.74M |
| March 31, 2023 | -4.822M |
| December 31, 2022 | -324.38M |
| September 30, 2022 | 4.602M |
| June 30, 2022 | -89.16M |
| March 31, 2022 | -37.29M |
| December 31, 2021 | -10.09M |
| September 30, 2021 | -26.81M |
| June 30, 2021 | -5.912B |
| March 31, 2021 | 737.13M |
| December 31, 2020 | 73.22M |
| September 30, 2020 | -279.64M |
| June 30, 2020 | -741.16M |
| Date | Value |
|---|---|
| March 31, 2020 | -60.08M |
| December 31, 2019 | -159.05M |
| September 30, 2019 | -159.66M |
| June 30, 2019 | -2.638M |
| March 31, 2019 | 166.05M |
| December 31, 2018 | 33.74M |
| September 30, 2018 | -190.85M |
| June 30, 2018 | -190.23M |
| March 31, 2018 | -47.15M |
| December 31, 2017 | -31.88M |
| September 30, 2017 | -203.35M |
| June 30, 2017 | -30.15M |
| March 31, 2017 | -3.574M |
| December 31, 2016 | -0.004M |
| September 30, 2016 | -1.531B |
| June 30, 2016 | -206.27M |
| March 31, 2016 | -12.00M |
| December 31, 2015 | -3.44M |
| September 30, 2015 | -5.159M |
| June 30, 2015 | -12.02M |
| March 31, 2015 | 18.29M |
| December 31, 2014 | -14.17M |
| September 30, 2014 | -83.14M |
| June 30, 2014 | -13.13M |
| March 31, 2014 | -957.20M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Avadel Pharmaceuticals Plc | -8.788M |
| Perrigo Co. Plc | 349.40M |
| GH Research Plc | 6.295M |
| Cosmo NV | -- |
| Axsome Therapeutics, Inc. | -0.45M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 415.70M |
| Cash from Financing (Quarterly) | -994.50M |
| Free Cash Flow | 1.508B |
| Free Cash Flow Per Share (Quarterly) | 5.729 |
| Free Cash Flow to Equity (Quarterly) | 1.405B |
| Free Cash Flow to Firm (Quarterly) | 454.65M |
| Free Cash Flow Yield | 9.43% |